Crewe Advisors LLC Purchases New Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, HoldingsChannel reports. The firm acquired 1,173 shares of the company’s stock, valued at approximately $28,000.

Other large investors have also bought and sold shares of the company. Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC lifted its stake in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares in the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares in the last quarter. CWM LLC lifted its stake in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after acquiring an additional 2,442 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $38.92, for a total transaction of $450,732.52. Following the completion of the transaction, the chief financial officer now owns 112,933 shares of the company’s stock, valued at $4,395,352.36. The trade was a 9.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the transaction, the insider now directly owns 165,254 shares of the company’s stock, valued at $4,941,094.60. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,167,913 shares of company stock valued at $34,303,787 in the last quarter. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $40.36 on Friday. Hims & Hers Health, Inc. has a 52-week low of $9.14 and a 52-week high of $44.43. The stock’s 50-day simple moving average is $30.02 and its 200 day simple moving average is $23.12. The stock has a market capitalization of $8.82 billion, a P/E ratio of 91.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Needham & Company LLC lifted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.